Pulmatrix (NASDAQ:PULM) Posts Earnings Results, Beats Expectations By $1.71 EPS

Pulmatrix (NASDAQ:PULM) released its earnings results on Thursday. The biotechnology company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($2.00) by $1.71, FiscalAI reports.

Pulmatrix Stock Performance

Shares of NASDAQ PULM traded down $0.09 during mid-day trading on Thursday, hitting $1.51. The stock had a trading volume of 20,613 shares, compared to its average volume of 10,308. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.76. Pulmatrix has a 1 year low of $1.16 and a 1 year high of $5.50. The firm has a market cap of $5.51 million, a P/E ratio of -1.23 and a beta of 1.91.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC acquired a new position in Pulmatrix, Inc. (NASDAQ:PULM) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix has an average rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).